Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and ...

Halozyme is relatively low-beta and an ideal stock in the biotech sector for a covered call trade with good liquidity on ...

Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) yesterday and set a price target of ...

On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $49.25 which represents a decrease of $-0.05 or -0.10% from the prior close of $49.3. The stock opened at $49.35 ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme (HALO – Research Report) and keeping the price target at ...

On Monday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $51.77 which represents a decrease of $-0.84 or -1.60% from the prior close of $52.61. The stock opened at $52.6 ...

Market volatility in Q3 was driven by softer-than-expected US employment data, but resilient earnings and rate cuts led to a ...

The Board of Directors of TransAlta Corporation declared a quarterly dividend of $0.06 per common share payable on January 1, ...

Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant ...

Gladney Center for Adoption, one of the leading adoption services agencies in the country, today announced construction work has been completed on the enhancements to the Gladney home. This was funded ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...